AKYA vs. QTRX, MASS, FEIM, RPID, SEER, KEQU, NAUT, ODYS, OWLT, and INTT
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Quanterix (QTRX), 908 Devices (MASS), Frequency Electronics (FEIM), Rapid Micro Biosystems (RPID), Seer (SEER), Kewaunee Scientific (KEQU), Nautilus Biotechnology (NAUT), Odysight.Ai (ODYS), Owlet (OWLT), and inTEST (INTT). These companies are all part of the "measuring and control equipment" industry.
Akoya Biosciences vs.
Quanterix (NASDAQ:QTRX) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
In the previous week, Quanterix had 4 more articles in the media than Akoya Biosciences. MarketBeat recorded 7 mentions for Quanterix and 3 mentions for Akoya Biosciences. Quanterix's average media sentiment score of 0.33 beat Akoya Biosciences' score of -1.02 indicating that Quanterix is being referred to more favorably in the media.
Quanterix received 238 more outperform votes than Akoya Biosciences when rated by MarketBeat users. Likewise, 61.63% of users gave Quanterix an outperform vote while only 55.56% of users gave Akoya Biosciences an outperform vote.
Quanterix has higher revenue and earnings than Akoya Biosciences. Quanterix is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.
Quanterix has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
Quanterix has a net margin of -30.12% compared to Akoya Biosciences' net margin of -66.77%. Quanterix's return on equity of -11.74% beat Akoya Biosciences' return on equity.
Quanterix presently has a consensus price target of $15.60, indicating a potential upside of 224.32%. Akoya Biosciences has a consensus price target of $2.51, indicating a potential upside of 92.77%. Given Quanterix's stronger consensus rating and higher probable upside, research analysts clearly believe Quanterix is more favorable than Akoya Biosciences.
86.5% of Quanterix shares are held by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are held by institutional investors. 6.9% of Quanterix shares are held by insiders. Comparatively, 7.3% of Akoya Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Quanterix beats Akoya Biosciences on 14 of the 18 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:AKYA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy AKYA Stock Free AKYA Stock Alerts